Collegium Pharmaceutical has revealed its financial outlook for 2025, projecting total product revenues to fall between $735 million and $750 million. A significant driver of this growth is expected from Jornay PM, the company's ADHD treatment, with net revenues projected to exceed $135 million. This positions Jornay PM as a primary catalyst for the company's anticipated revenue gains, as reported on Collegium's official site.
In terms of profitability, Collegium anticipates its adjusted EBITDA, excluding stock-based compensation, to range from $435 million to $450 million. Likewise, the company expects adjusted operating expenses to be between $220 million and $230 million, reflecting a strategic balance between growth investment and cost management.
To support this growth trajectory, Collegium is set to make targeted investments in Jornay PM throughout 2025, aiming to build momentum into 2026. The company has also completed the incorporation of Ironshore Therapeutics Inc., strengthening its position within the neurology market. Simultaneously, Collegium executed a $60 million share repurchase under its $150 million program, underscoring confidence in its financial health and strategic direction.